Author

M. Kluever

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

S. Becker· 3 shared S. Halwe· 3 shared A. Kupke· 2 shared A. Werner· 2 shared C. Kreer· 2 shared C. Rohde· 2 shared F. Klein· 2 shared H. Gruell· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

S. Becker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults

M. S. Ercanoglu, L. Gieselmann, S. Daehling, N. Poopalasingam, S. Detmer, M. Koch, M. Korenkov, S. Halwe, M. Kluever, V. Di Cristanziano, U. H. Janicki, M. Schlotz, J. Worczinski, B. Gathof, H. Gruell, , F. Klein

The paper analyzes B cell immunity in unexposed adults and finds no substantial pre-existing antibody or B cell response to SARS-CoV-2.

bioRxiv · Sep 8, 2021Immunology

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

S. Halwe, A. Kupke, K. Vanshylla, F. Liberta, H. Gruell, M. Zehner, C. Rohde, V. Kraehling, M. Gellhorn-Serra, C. Kreer, M. Kluever, L. Sauerhering, J. Schmidt, Z. Cai, F. Han, , S. Becker

This paper describes a monoclonal antibody, DZIF-10c, that effectively neutralizes SARS-CoV-2 and its variants when administered intranasally to mice, offering potential for topical treatment.

bioRxiv · Jun 9, 2021Microbiology

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A. Tscherne, J. H. Schwarz, C. Rohde, A. Kupke, G. Kalodimou, L. Limpinsel, N. M. A. Okba, B. Bosnjak, I. Sandrock, S. Halwe, L. Sauerhering, K. Printz, L. Nan, E. Duell, S. Jany, , A. Volz

This paper describes the preclinical evaluation of MVA-SARS-2-S, a vector vaccine against SARS-CoV-2, showing it induces immune responses and protects mice from infection.

bioRxiv · Jan 9, 2021Microbiology